Want to Subscribe?
Read Corporate India and add to your Business Intelligence
Unlock Unlimited Access
Published: March 15, 2026
Updated: March 15, 2026
| BSE ticker code | 524816 |
| NSE ticker code | NATCOPHARM |
| Major activity | Pharmaceuticals |
| CMD | Venkaiah Chowdary Nannapaneni |
| Equity capital | Rs 35.82 crore; FV Rs 02 |
| 52 week high/low | Rs 1060 / Rs 660 |
| CMP | Rs 888.65 |
| Market Capitalisation | Rs 15916.60 crore |
| Recommendation | Accumulate |
Hyderabad-headquartered Natco Pharma is a globally recognised, vertically integrated and R&D-focused generic drug manufacturing company engaged in the development and manufacture of high-quality and niche finished dosage forms (FDF) and active pharmaceutical ingredients (API). It has established its presence in all three business segments — FDF, API and contract manufacturing.
Focused on the niche pipeline to drive growth over the years, Natco has constantly showcased its expertise through the launch of niche, highvalue products including Para IV and first-to-file (FTF) products in India and the US while expanding into new geographies. The company follows a blockbuster launch strategy focusing on complex, high-barrier-to-entry generics and niche molecules, leveraging its R&D capabilities to develop challenging difficult-to-manufacture products.
Notable blockbuster products launched in the past include generic Revlimid, Glatiramer Acetate injection, Liposomal Doxorubicin, Sofosbuvir for Hepatitis-C and Dabigatran.
The management has reiterated its commitment to building a robust and niche product pipeline to drive sustained earnings, growth. Following the successful launch of generic revlimid, the company is optimistic about unlocking additional significant opportunities over the next couple of years. A key highlight of Natco’s strategy is its focus on the US market, where its pipeline is particularly strong, emphasising complex generics and first-to-file (FTF) opportunities. These high-barrier-entry products, such as semaglutide injections for diabetes and weight loss, are central to the company’s growth strategy.
Natco has made rapid growth in its financial performance. During the last 12 years, its sales turnover has surged over six times from Rs 739 crore in fiscal 2014 to Rs 4,430 crore in fiscal 2025, with operating profit shooting up over 12 times from Rs 179 crore to Rs 2,196 crore and the net profit taking a jump of around 20 times from Rs 1,798 crore to Rs 1,883 crore. What is more, prospects ahead are all the more encouraging. Consider:
The company's financial position is very strong, with reserves at the end of September 2025 standing at Rs 8,614 crore - almost 240 times its equity capital of Rs 36 crore. It has reduced its borrowings from Rs 416 crore in fiscal 2022 to Rs 261 crore by September 2025. Its interest burden is nominal - just Rs 36 crore in the context of sales of Rs 4,560 crore. What is more, it has a net cash balance of Rs 2,500 crore. Natco subsidiaries, particularly in Canada and Brazil, are doing very well. The management expects growth momentum in the subsidiaries to continue as the latter have a good pipeline of products pending approval.
The company made its maiden entry into the crop protection space with the launch of a pheromone product, Natmate. It also launched CTPR pesticides subsequently. The management has set a crop sciences business revenue target of Rs 120-150 crore for fiscal 2026.
PERFORMANCE INDICATORS (Rs. in crore)
| Year | Net Sales | Net Profit | EPS (Rs.) | Div (%) | BV (%) |
|---|---|---|---|---|---|
| 2024-25 | 4429.50 | 1884.25 | 105.20 | 300.0 | 482.90 |
| 2025-26 (E) | 4643.26 | 1976.42 | 109.44 | 300.0 | 491.40 |
| 2026-27 (E) | 4931.56 | 2069.42 | 112.46 | 325.0 | 496.52 |
| BSE ticker code | 544117 |
| NSE ticker code | SIGNPOST |
| Major activity | Advertising & Media |
| Chairman | Girish Pandurang Kulkarni |
| Equity capital | Rs 10.69 crore; FV Rs 02 |
| 52 week high/low | Rs 312 / Rs 179 |
| CMP | Rs 242.00 |
| Market Capitalisation | Rs 1293.49 crore |
| Recommendation | Accumulate at declines |
One of the leading players in India’s out-of-home (OOH) advertising space, Signpost India is among the top three players nationwide. Since its inception in 2008, the Mumbai-headquartered company has expanded across locations, including Delhi, Bangalore, Chennai, Kolkata, Nagpur, Pune, Nashik and Aurangabad. Today, it operates more than 12,500 advertising assets across more than 25 cities, including ads at transit locations (like airports, metros), bus shelters and city roads, digital screens and traditional outdoor billboards, catering to over 1,600 active clients.
The company uses all such places for display of advertisements through design technology, data analytics and content provision. With demonstrable experience, it engineers end-to-end mega projects to build public places that ensure commuter convenience, ergonomic roofing and priority seating, tactile flooring, accessibility ramps, charging stations, laboratories, SOS integration, notifications of upcoming buses, and more.
The company has long-term plans averaging 14 years and uses its in-house captive media platform to plan and direct relationships and over 25,000 premium digital panels. It boasts of a strong clientele list with names like Sony, Samsung, Nestle, Havells, Air Asia, TVS, Viacom, Zepto, Sketchers and WeWork.
Its digital spaces have driven multi-city campaigns for brands, garnering recognition across both national and international arenas for innovation, design, sustenance and engineering and receiving awards in numerous categories, including 57 golds, 43 silvers and 28 bronzes from prestigious bodies like the Abbys, the London Digital Signage Awards, and the Kyoorius awards.
Needless to say, the company has made rapid strides on the financial front since its inception in 2008 and its listing on BSE and NSE in 2021. The sales turnover, which had shot up from Rs 43 crore in 2015 to Rs 168 crore in fiscal 2022, has during the last four years surged to Rs 525 crore in fiscal 2025. Operating profit, which had jumped 12 times from Rs 5 crore in fiscal 2012 to Rs 60 crore in fiscal 2022, climbed further to cross Rs 100 crore and reach Rs 116 crore in fiscal 2025. Net profit, which had risen from Rs 3 crore in 2015 to Rs 28 crore in 2022, skyrocketed to Rs 50 crore in 2025. What is more, prospects ahead are all the more promising Consider:
PERFORMANCE INDICATORS (Rs. in crore)
| Year | Net Sales | Net Profit | EPS (Rs.) | Div (%) | BV (%) |
|---|---|---|---|---|---|
| 2024-25 | 453.22 | 34.10 | 6.40 | 25.0 | 46.90 |
| 2025-26 (E) | 469.36 | 36.44 | 6.90 | 25.0 | 48.36 |
| 2026-27 (E) | 475.25 | 40.15 | 7.20 | 30.0 | 51.32 |
| BSE ticker code | 505685 |
| NSE ticker code | -- |
| Major activity | Iron & Steel Products |
| Chairman | Narayan Tulsiram Atal |
| Equity capital | Rs 15.18 crore; FV Rs 10 |
| 52 week high/low | Rs 28 / Rs 10 |
| CMP | Rs 19.71 |
| Market Capitalisation | Rs 29.92- crore |
| Recommendation | Buy |
Popularly described as ‘toolmaker to the nation’, Mumbai-headquartered Taparia Tools, set up in 1969 in technological collaboration with Banco, a reputed Swedish company, is engaged in the manufacture of top-quality hand tools. These include:
The company has a well laid out, fully equipped factory located at Nashik, which is a four-hour drive from Mumbai, and another expanded unit at Goa, 600 km from Mumbai.
The plant is located on a total area of 42,832 sq m. All the manufacturing facilities required for production of hand tools are under one roof. Hand tools manufacturing is complicated, involving high technology and a labour-intensive production process. Of the total workforce of 1,200, the number of people engaged in direct production is 1,000. The remaining are in administration and management.
The company’s R&D department is manned by mechanical engineers and metallurgists equipped with the latest CAD design facilities, etc. From its inception, the company has laid high emphasis on the quality of its products. It has a wellestablished quality control department to monitor different stages of production. In fact, Taparia tools meet and in some cases exceed US Federal Specifications of hardness and torque value, besides meeting Indian, British and German standards.
TTL is an undisputed leader in the space of hand tools in India, and has over 800 distributors across the country. What is more, the company is spreading its footprint overseas. By now, it exports its products to over 25 countries, including the UK, the US, Denmark, Germany, Sweden, Israel, Norway, Finland, Dubai, Kuwait, UAE, Tanzania, Kenya, Argentina, Uruguay, Hong Kong, Thailand, Mexico and Sri Lanka.
Needless to say, the company is growing steadily on the financial front. During the last 12 years, its sales turnover has expanded more than three and a half times from Rs 266 crore in fiscal 2014 to Rs 913 crore in fiscal 2025, with operating profit shooting up more than seven and a half times from Rs 20 crore to Rs 156 crore and the profit at net level surging more than 10 times from Rs 12 crore to Rs 123 crore. In the current year, sales will cross the Rs 1,000-crore mark with net profit expected to reach the Rs 150-crore level. What is, more prospects for the company going ahead are all the more promising. Consider:
PERFORMANCE INDICATORS (Rs. in crore)
| Year | Net Series | Net Profit | EPS (Rs.) | Div (%) | BV (%) |
|---|---|---|---|---|---|
| 2024-25 | 912.89 | 122.55 | 80.70 | 500.0 | 268.90 |
| 2025-26 (E) | 946.15 | 132.46 | 86.10 | 500.0 | 272.46 |
| 2026-27 (E) | 998.62 | 138.62 | 88.60 | 500.0 | 280.12 |
March 31, 2026 - Second Issue
Industry Review
Want to Subscribe?
Read Corporate India and add to your Business Intelligence
Unlock Unlimited Access
Lighter Vein
Popular Stories
Archives